Computer modeling for ocular drug delivery

Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems

Volumn , Issue , 2012, Pages 59-93

  Missel, Paul J ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938201303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12950     Document Type: Chapter

References (63)

1. Acton JR, Squire PT. 1985. Solving Equations with Physical Understanding. Bristol, UK: Adam Hilger, Sections 8.5-8.6.
2. Amrite AC, Edelhauser HF, Kompella UB. 2008. Modeling of corneal and retinal pharmaco-kinetics after periocular drug administration. IOVS, 49, 320-32.
3. Araie M, Maurice DM. 1991. The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextrane from the vitreous by the anterior and retinal pathways. Exp Eye Res, 52, 27-39.
4. Balachandran RK, Barocas VH. 2008. Computer modeling of drug delivery to the posterior eye: Effect of active transport and loss to choroidal blood flow. Pharm Res, 25, 2685-96.
5. Balachandran RK, Barocas VH. 2011. Contribution of saccadic motion to intravitreal drug transport: Theoretical analysis. Pharm Res, 28, 1049-64.
6. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters III GB, Miller M. 2003. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology, 110, 681-6.
7. Bito LZ, Salvador EV. 1972. Intraocular fluid dynamics III. The site and mechanism of pros-taglandin transfer across the blood intraocular fluid barriers. Exp Eye Res, 14, 233-41.
8. Bron AJ, Tripathi RC, Tripathi BJ. 1997. Wolff’s Anatomy of the Eye and Orbit, 8th ed. New York: Chapman & Hall, Chapter 8.
9. Chan JE, Pridgen TA, Csaky KG. 2010. Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon’s implant in the rat. Exp Eye Res, 90, 501-6.
10. Chang-Lin J-E, Burke JA, Peng Q, et al. 2011. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. IOVS 52:4605-9.
11. Crank J. 1975. The Mathematics of Diffusion. London: Oxford University Press, Section 6.3.4, Surface Diffusion.
12. Cunha-Vaz J, Maurice D. 1969. Fluorescein dynamics in the eye. Doc Ophthalmol, 26, 61-72.
13. Fatt I, Hedbys B. 1970. Flow of water in the sclera. Exp Eye Res, 10, 243-9.
14. Friedrich S. 1996. Ocular pharmacokinetic modeling. PhD diss., Toronto, ON: University of Toronto.
15. Friedrich S, Cheng Y-L, Saville B. 1997. Finite element modeling of drug distribution in the vitreous humor of the rabbit eye. Ann Biomed Eng, 25, 303-14.
16. Funk RH, Gehr J, Rohen JW. 1992. Short-term hemodynamic changes in episcleral arteriove-nous anastomoses correlate with venous pressure and IOP changes in the albino rabbit. Curr Eye Res, 15, 87-93.
17. Harte J. 1988. Consider a spherical cow: A course in environmental problem solving. Sausalito: University Science Books.
18. Heys JJ, Barocas VH. 2002a. A Boussinesq model of natural convection in the human eye and the formation of Krukenberg’s spindle. Ann Biomed Eng, 30, 392-401.
19. Heys JJ, Barocas VH. 2002b. Computational evaluation of the role of accommodation in pig-mentary glaucoma. IOVS, 43, 700-8.
20. Hopfenberg HP. 1976. Controlled release from erodible slabs, cylinders, and spheres. In Controlled Release from Polymeric Formulations, ed. DR Paul and FW Harris, 26-31. Washington, DC: American Chemical Society Symposium Series 33.
21. Johnson F, Maurice D. 1984. A simple method of measuring aqueous humor flow with intra-vitreal fluoresceinated dextrans. Exp Eye Res, 39, 791-805.
22. Keister JC. 1987. An experimental modeling method for the analysis of diffusion through thin membranes. J Membrane Sci, 35, 73-89.
23. Keister JC. 1988. Drug transport predicted from measurements of voltage in a water-filled stainless steel model of the eye. Alcon Laboratories, unpublished results.
24. Kim H, Csaky KG, Gravlin L, et al. 2006. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina, 26, 523-30.
25. Kotliar K, Maier M, Bauer S, Feucht N, Lohman C, Lanzl I. 2007. Effect of intravitreal injec-tions and volume changes on intraocular pressure: Clinical results and biomechanical model. Acta Ophthalmol Scand, 85, 777-81.
26. Lee B, Litt M, Buchsbaum G. 1992. Rheology of the vitreous body, part I: Viscoelasticity of the human vitreous. BioRheol, 29, 521-33.
27. Lee B, Litt M, Buchsbaum G. 1994. Rheology of the vitreous body, part II: Viscoelasticity of bovine and porcine vitreous. BioRheol, 31, 327-38.
28. Lee SS, Ghosn C, Yu Z, et al. 2010. Vitreous VEGF clearance is increased after vitrectomy. IOVS, 51, 2135-8.
29. Lee SS, Robinson MR. 2009. Novel drug delivery systems for retinal diseases. Ophthalmic Res, 41, 124-35.
30. Lin H-H. 1997. Finite element modeling of drug transport processes after an intravitreal injec-tion. Master’s diss., Toronto, ON: University of Toronto.
31. Luu KT, Zhang EY, Prasanna G, et al. 2009. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270). J Ocular Pharm Ther, 331, 627-35.
32. Maurice DM. 1959. Protein dynamics in the eye studied with labelled proteins. Am J Ophthalmol, 47, 361-7.
33. Maurice DM. 1976. Injection of drugs into the vitreous body. In Symposium on Ocular Therapy, ed. T. Leopold and R. Burns, 59-72. London: Wiley.
34. Maurice DM. 1987. Flow of water between aqueous and vitreous compartments of the rabbit eye. Am J Physiol 252:F104-8.
35. Missel PJ. 2000. Finite element modeling of diffusion and partitioning in biological systems: The infinite composite medium problem. Ann Biomed Eng, 28, 1307-17.
36. Missel PJ. 2002a. Finite and infinitesimal representations of the vasculature: Ocular drug clearance by vascular and hydraulic effects. Ann Biomed Eng, 30, 1128-39.
37. Missel PJ. 2002b. Hydraulic flow and vascular clearance influences on intravitreal drug deliv-ery. Pharm Res, 19, 1636-47.
38. Missel PJ. 2009. Computer modeling of pharmacokinetics from ocular drug delivery. Lecture presented at the Association for Research in Vision and Ophthalmology Summer Eye Research Conference on Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases, Basic Research to Clinical Application, Bethesda, MD, July 31-August 1 2009.
39. Missel PJ. 2012. Simulating intravitreal injections in anatomically accurate models for rabbit, monkey and human eyes. Pharm Res. DOI 10.1007/s11095-012-0721-9.
40. Missel PJ, Chastain JE, Kiehlbauch CC, Dahlin DC. 2003. Predicting ocular drug levels from intravitreal administration of anecortave acetate (AL-3789). Poster presented at the annual meeting of the Biomedical Engineering Society, Nashville, TN, October 1-4 2003.
41. Missel PJ, Chastain JE, Mitra A, et al. 2010a. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the poste-rior segment. J Ocular Pharmacol Ther, 26, 137-45.
42. Missel PJ, Horner M, Muralikrishnan R. 2010b. Dissolution of intravitreal triamcinolone ace-tonide suspensions in an anatomically accurate rabbit eye model. Pharm Res, 27, 1530-46.
43. Missel PJ, Stevens L, Chastain J, Yaacobi Y. 2006. A clear vision for drug delivery. Fluent News 15:s8-s10.
44. Missel PJ, Stevens LE, Mauger JW. 2004. Dissolution of anecortave acetate in a cylindrical flow cell: Re-evaluation of convective diffusion/drug dissolution for sparingly soluble drugs. Pharm Dev Tech, 9, 453-9.
45. Missel PJ, Yaacobi Y. 2011. Drug delivery device, US Patent 7,943,162.
46. Molokhia SA, Jeong E-K, Higuchi WI, Li SK. 2009. Transscleral iontophoretic and intravit-real delivery of a macromolecule: Study of ocular distribution in vivo and postmortem with MRI. Exp Eye Res, 88, 418-25.
47. Ohtori A, Tojo K. 1994. In vivo/in vitro correlation of intravitreal delivery of drugs with the help of computer simulation. Biol Pharm Bull, 17, 283-90.
48. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. 1995. Human scleral permeability: Effects of age, cryotherapy, trans-scleral diode laser, and surgical thinning. IOVS, 36, 1893-903.
49. Park J, Bungay PM, Lutz RJ, et al. 2005. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release, 105, 279-95.
50. Peeters L, Sanders NN, Braeckmans K, et al. 2005. Vitreous: A barrier to nonviral ocular gene therapy. IOVS, 46, 3553-61.
51. Prausnitz MR, Noonan JS. 1998. Permeability of cornea, sclera and conjunctiva: A literature analysis for drug delivery to the eye. J Pharm Sci, 87, 1479-88.
52. Ranta V-K, Mannermaa E, Lummepuro K, et al. 2010. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release, 148, 42-8.
53. Reitsamer HA, Bogner B, Tockner B, Kiel JW. 2009. Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits. IOVS, 50, 2301-7.
54. Rim JE, Pinsky PM, van Osdol WW. 2005. Finite element modeling of coupled diffusion with partitioning in transdermal drug delivery. Ann Biomed Eng, 33, 1422-38.
55. Robinson MR, Lee SS, Kim H, et al. 2006. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res, 82, 479-87.
56. Sappington RS, Carlson BJ, Crish SD, Calkins DJ. 2010. The microbead occlusion model: A paradigm for induced ocular hypertension in rats and mice. IOVS 51:207-16.
57. Sebag J. 1987. Age-related changes in human vitreous structure. Graefes Arch Clin Exp Ophthalmol, 225, 89-93.
58. Stay MS, Xu J, Randolph TW, Barocas VH. 2003. Computer simulation of convective and dif-fusive transport of controlled-release drugs in the vitreous humor. Pharm Res, 20, 96-102.
59. To C, Kong C, Chan C, Shahidullah M, Do C. 2002. The mechanism of aqueous humour for-mation. Clin Exp Optom, 85, 335-49.
60. Tojo K. 2004. A pharmacokinetic model for ocular drug delivery. Chem Pharm Bull, 52, 1290-4.
61. Tojo K, Nakagawa K, Morita Y, Ohtori A. 1999. A pharmacokinetic model of intravitreal delivery of ganciclovir. Eur J Pharm Biopharm, 47, 99-104.
62. Urcola JH, Hernandez M, Vecino E. 2006. Three experimental glaucoma models in rats: Comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp Eye Res, 83, 429-37.
63. Xu J, Heys JJ, Barocas VH, Randolph TW. 2000. Permeability and diffusion in vitreous humor: Implications for drug delivery. Pharm Res 17:664-9